KalVista Pharmaceuticals, Inc. - Common Stock (KALV)
Frequently Asked Questions About KalVista Pharmaceuticals, Inc. - Common Stock (KALV)
How can investors learn more about KalVista Pharmaceuticals?
Investors can learn more about KalVista Pharmaceuticals through its official website, where they can find detailed information including press releases, financial reports, and updates on clinical trials. The company also shares information through investor presentations and participates in industry conferences to provide insights into its research and development efforts.
How does KalVista collaborate with other companies?
KalVista engages in strategic collaborations with pharmaceutical and academic organizations to enhance its research capabilities and accelerate drug development. These partnerships can involve sharing expertise, resources, and funding, allowing KalVista to leverage combined strengths in pursuing innovative treatments.
How does KalVista ensure the safety and efficacy of its drugs?
KalVista Pharmaceuticals ensures the safety and efficacy of its drugs through rigorous clinical trials that comply with regulatory standards set by agencies like the FDA. The company conducts preclinical studies followed by multiple phases of clinical trials, collecting extensive data on the effects of its therapies before seeking regulatory approval.
How does KalVista handle regulatory approvals?
KalVista Pharmaceuticals manages regulatory approvals by adhering to stringent guidelines set forth by the U.S. Food and Drug Administration (FDA) and other regulatory bodies. The company prepares comprehensive submissions detailing clinical trial results and safety data to seek marketing approval for its drug candidates, ensuring compliance and thoroughness.
How does KalVista Pharmaceuticals fund its research?
KalVista Pharmaceuticals funds its research through a combination of equity financing, grants, and collaborations with larger pharmaceutical companies. The company raises capital through public stock offerings and strategic partnerships, allowing it to advance its clinical trials and research programs effectively.
What are the future goals of KalVista Pharmaceuticals?
KalVista Pharmaceuticals aims to advance its clinical programs and successfully bring its lead candidates to market, particularly KVD900 for HAE and KVD001 for DME. Additionally, the company is committed to expanding its pipeline and exploring new therapeutic opportunities that align with its expertise in the kinin system.
What are the main products in KalVista’s pipeline?
KalVista's pipeline includes several promising candidates targeting hereditary angioedema and diabetic macular edema. Notably, KVD900 is being investigated for its potential to treat HAE, while KVD001 is a candidate aimed at treating diabetic macular edema, showcasing the company's commitment to developing effective therapies for unmet medical needs.
What does KalVista Pharmaceuticals, Inc. do?
KalVista Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases that involve the kinin system. The primary focus of the company is on treatments for hereditary angioedema (HAE) and diabetic macular edema (DME), utilizing its proprietary technology to develop oral therapeutics.
What has been KalVista's clinical development status?
KalVista Pharmaceuticals is currently in various stages of clinical development for its lead candidates. KVD900 has advanced to late-stage clinical trials for HAE, while KVD001 is undergoing trials for diabetic macular edema, indicating progress in translating their research into potential therapies for patients.
What is diabetic macular edema (DME)?
Diabetic macular edema (DME) is a complication of diabetes that results from fluid accumulation in the macula, leading to vision impairment and potential blindness. DME affects many individuals with diabetes, particularly those with poorly controlled blood sugar levels. KalVista's research aims to develop new treatments to effectively address this condition.
What is hereditary angioedema (HAE)?
Hereditary angioedema (HAE) is a rare genetic condition characterized by recurrent episodes of severe swelling in various parts of the body, including the limbs, abdomen, and airway. These episodes can be life-threatening; hence, timely treatment is essential. KalVista focuses on developing therapies that provide effective management of this condition.
What is KalVista’s approach to intellectual property?
KalVista Pharmaceuticals places a strong emphasis on protecting its intellectual property through patents and trademarks. The company actively seeks to secure its proprietary technologies and drug candidates to maintain a competitive advantage in the biopharmaceutical industry, facilitating future innovations and partnerships.
What is the current stock performance of KalVista Pharmaceuticals?
The stock performance of KalVista Pharmaceuticals, traded under the ticker KALV on NASDAQ, can fluctuate based on various factors, including clinical trial results, market trends, and overall investor sentiment in the biotech sector. For the latest performance metrics, stakeholders should refer to financial news platforms for real-time updates.
What is the primary focus of KalVista's research?
KalVista's research primarily focuses on addressing diseases linked to the kinin system, particularly hereditary angioedema (HAE) and diabetic macular edema (DME). The company aims to develop novel oral medications that can effectively manage these conditions by targeting specific proteins involved in the kinin pathway.
What is the significance of KVD900 in KalVista's pipeline?
KVD900 is significant in KalVista's pipeline as it represents the company's lead candidate aimed at treating hereditary angioedema. Its development reflects KalVista's strategic focus on addressing critical unmet medical needs in this area, and it is designed to offer a potentially effective oral treatment option for managing HAE attacks.
What role does the kinin system play in disease?
The kinin system is a complex network of proteins and enzymes that plays crucial roles in inflammation, blood pressure regulation, and vascular permeability. Dysregulation of this system can lead to various diseases, including hereditary angioedema and other inflammatory conditions, which is why KalVista targets this pathway in its drug development efforts.
When did KalVista Pharmaceuticals go public?
KalVista Pharmaceuticals went public in 2016, listing its shares on the NASDAQ under the ticker symbol 'KALV'. The initial public offering (IPO) allowed the company to raise significant capital to fund its drug development initiatives and expand its research programs.
Where is KalVista Pharmaceuticals, Inc. headquartered?
KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. The location is central to Massachusetts’ vibrant biotechnology and pharmaceutical ecosystem, providing access to a wealth of talent and resources in the life sciences field.
Who are KalVista’s competitors?
KalVista competes with other biotechnology and pharmaceutical companies that focus on treatments for rare diseases and eye disorders. Key competitors include Takeda Pharmaceuticals, which offers treatments for HAE, and numerous companies developing therapies for diabetic macular edema, such as Regeneron Pharmaceuticals and Novartis.
Who are the key leaders at KalVista Pharmaceuticals?
KalVista Pharmaceuticals is led by a team of experienced professionals in the biopharmaceutical industry. The executive team includes individuals with extensive backgrounds in drug development, clinical research, and corporate strategy, ensuring that the company remains at the forefront of innovation in its therapeutic areas.
What is the current price of KalVista Pharmaceuticals, Inc. - Common Stock?
The current price of KalVista Pharmaceuticals, Inc. - Common Stock is 11.09
When was KalVista Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of KalVista Pharmaceuticals, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock?
The market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock is 379.65M
How many shares of KalVista Pharmaceuticals, Inc. - Common Stock are outstanding?
KalVista Pharmaceuticals, Inc. - Common Stock has 34.23M shares outstanding.